757 related articles for article (PubMed ID: 26710887)
1. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.
Laubach J; Garderet L; Mahindra A; Gahrton G; Caers J; Sezer O; Voorhees P; Leleu X; Johnsen HE; Streetly M; Jurczyszyn A; Ludwig H; Mellqvist UH; Chng WJ; Pilarski L; Einsele H; Hou J; Turesson I; Zamagni E; Chim CS; Mazumder A; Westin J; Lu J; Reiman T; Kristinsson S; Joshua D; Roussel M; O'Gorman P; Terpos E; McCarthy P; Dimopoulos M; Moreau P; Orlowski RZ; Miguel JS; Anderson KC; Palumbo A; Kumar S; Rajkumar V; Durie B; Richardson PG
Leukemia; 2016 May; 30(5):1005-17. PubMed ID: 26710887
[TBL] [Abstract][Full Text] [Related]
2. When to recommend a second autograft in patients with relapsed myeloma?
Ziogas DC; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Apr; 58(4):781-787. PubMed ID: 27894207
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; Vangsted A; Weisel K; Baz R; Hungria V; Berdeja JG; Leal da Costa F; Maiolino A; Waage A; Vesole DH; Ocio EM; Quach H; Driessen C; Bladé J; Leleu X; Riva E; Bergsagel PL; Hou J; Chng WJ; Mellqvist UH; Dytfeld D; Harousseau JL; Goldschmidt H; Laubach J; Munshi NC; Gay F; Beksac M; Costa LJ; Kaiser M; Hari P; Boccadoro M; Usmani SZ; Zweegman S; Holstein S; Sezer O; Harrison S; Nahi H; Cook G; Mateos MV; Rajkumar SV; Dimopoulos MA; Richardson PG
Lancet Oncol; 2021 Mar; 22(3):e105-e118. PubMed ID: 33662288
[TBL] [Abstract][Full Text] [Related]
4. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice].
Kuroda J
Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849
[TBL] [Abstract][Full Text] [Related]
6. The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma.
Hagen PA; Stiff P
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e98-e107. PubMed ID: 30537552
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
8. Conventional therapy and approach to management.
Rajkumar SV; Kyle RA
Best Pract Res Clin Haematol; 2005; 18(4):585-601. PubMed ID: 16026739
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of relapsed or refractory multiple myeloma].
Tsurumi H
Nihon Rinsho; 2015 Jan; 73(1):114-8. PubMed ID: 25626315
[TBL] [Abstract][Full Text] [Related]
10. Management of relapsed multiple myeloma after autologous stem cell transplant.
Holstein SA; Richardson PG; Laubach JP; McCarthy PL
Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
[TBL] [Abstract][Full Text] [Related]
11. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
Palumbo A; Sezer O; Kyle R; Miguel JS; Orlowski RZ; Moreau P; Niesvizky R; Morgan G; Comenzo R; Sonneveld P; Kumar S; Hajek R; Giralt S; Bringhen S; Anderson KC; Richardson PG; Cavo M; Davies F; Bladé J; Einsele H; Dimopoulos MA; Spencer A; Dispenzieri A; Reiman T; Shimizu K; Lee JH; Attal M; Boccadoro M; Mateos M; Chen W; Ludwig H; Joshua D; Chim J; Hungria V; Turesson I; Durie BG; Lonial S;
Leukemia; 2009 Oct; 23(10):1716-30. PubMed ID: 19494840
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
[TBL] [Abstract][Full Text] [Related]
13. Choosing treatment options for patients with relapsed/refractory multiple myeloma.
Castelli R; Orofino N; Losurdo A; Gualtierotti R; Cugno M
Expert Rev Anticancer Ther; 2014 Feb; 14(2):199-215. PubMed ID: 24329153
[TBL] [Abstract][Full Text] [Related]
14. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.
Dingli D; Ailawadhi S; Bergsagel PL; Buadi FK; Dispenzieri A; Fonseca R; Gertz MA; Gonsalves WI; Hayman SR; Kapoor P; Kourelis T; Kumar SK; Kyle RA; Lacy MQ; Leung N; Lin Y; Lust JA; Mikhael JR; Reeder CB; Roy V; Russell SJ; Sher T; Stewart AK; Warsame R; Zeldenrust SR; Rajkumar SV; Chanan Khan AA
Mayo Clin Proc; 2017 Apr; 92(4):578-598. PubMed ID: 28291589
[TBL] [Abstract][Full Text] [Related]
15. [Current treatment of refractory and relapsed multiple myeloma].
Sasaki M
Rinsho Ketsueki; 2016; 57(10):2084-2095. PubMed ID: 27795518
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
17. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
Siegel DS; Vij R; Jakubowiak AJ
Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
[TBL] [Abstract][Full Text] [Related]
18. [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)].
Lokhorst H; Huijgens PC; Raymakers R; Bos GM; Vellenga E; Wijermans PW; Sonneveld P;
Ned Tijdschr Geneeskd; 2005 Apr; 149(15):808-13. PubMed ID: 15850271
[TBL] [Abstract][Full Text] [Related]
19. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
20. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
Olin RL; Vogl DT; Porter DL; Luger SM; Schuster SJ; Tsai DE; Siegel DL; Cook RJ; Mangan PA; Cunningham K; Stadtmauer EA
Bone Marrow Transplant; 2009 Mar; 43(5):417-22. PubMed ID: 18850013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
